How a new era of weight management services can reduce obesity-related health inequalities
Executive summary
The UK is at an inflection point in how it treats obesity. After decades of modest clinical progress and widening inequality, the arrival of GLP-1 and dual GIP/GLP-1 receptor agonists has changed what is achievable. The treatment paradigm has shifted from short-term weight loss attempts to long-term, multimodal management of a chronic condition. The decisions taken on how the NHS rolls out these medicines over the next 18 months will determine whether this becomes the moment obesity-related health inequalities begin to narrow, or the moment they are entrenched for a generation.
The risk
Obesity is one of the most unequal public health challenges facing the UK, and the inequality is deepening. It costs the economy £126 billion a year, and the burden falls hardest across deprivation, ethnicity, disability and childhood, and on the populations the existing system has historically been least able to reach. Early evidence on access to new weight management treatments suggests the same pattern is repeating: people in the most deprived areas are accessing 32% fewer GLP-1 prescriptions than those in the least deprived, despite carrying a substantially higher obesity burden. Without deliberate action, the most significant clinical advance in obesity treatment in a generation risks excluding the populations who need it most.
The opportunity
The clinical, technological and delivery infrastructure required to transform obesity care is maturing in parallel. New pharmacotherapy delivers weight loss at a magnitude previously achievable only through surgery. Digital infrastructure has matured into a credible national delivery channel, capable of reaching working-age adults, those in deprived areas and those geographically distant from specialist services. Community-anchored providers have demonstrated reach into underserved populations that standard pathways miss. Used together, these capabilities make it possible to deliver effective treatment to the populations carrying the greatest burden, with outcomes that match or exceed those seen in the general population, at the scale population-level impact requires. This directly supports the Ten Year Health Plan’s three shifts: hospital to community, analogue to digital, and sickness to prevention.
Recommendations
The ask
What stands between the clinical possibility and the equitable outcome is implementation. Provider readiness, inclusive digital infrastructure, operational design, and the visibility of equity duties are all solvable with existing policy levers. This white paper sets out six commissioning reforms for NHS England, DHSC and Integrated Care Boards to ensure the rollout narrows the obesity inequalities gap rather than widening it
What we are calling for
- A national equity dashboard for GLP-1 commissioning. NHS England should publish uptake, completion and outcomes by deprivation, ethnicity, sex and disability, with automatic regional review triggered where disparities widen for two consecutive quarters
- Primary care incentives that reward equitable referral. The 2026/27 GP contract should reward practices specifically for reaching patients experiencing the greatest health inequalities, with capacity matched to the under-resourced practices serving those communities
- NHS England should pilot a digitally enabled obesity prescription pathway in which approved digital providers can initiate GLP-1 prescribing following a GP referral. As with NHS Pharmacy First, clinical suitability would be assessed within the pathway against agreed criteria and care would be co-ordinated with GPs through the shared care record. Evaluation of the pilot programme should compare the reach into underserved groups and clinical outcomes against the existing pathway
- An Obesity Transformation Fund. DHSC and NHS England should establish a time-limited fund to commission integrated obesity care, combining pharmacotherapy with behavioural and digital wraparound, distributed equitably and tracked against health-inequalities metrics
- Barrier-based triage piloted alongside clinical-complexity triage. NHS England and ICBs should pilot need-based triage models that match support intensity to the barriers holding patients back, not solely based on clinical complexity – with evaluation of cost per outcome and patient experience
- Formal commissioning of the maintenance phase. NHS England should commission the Stage 3 maintenance phase already identified in the tirzepatide pathway as a funded service beginning at BSOP completion or pharmacotherapy down-titration, with 12-month and 24-month outcome reporting stratified by deprivation, ethnicity, sex and disability
Future Health Research was commissioned by Voy to develop this White Paper, to discuss the research and recommendations please contact Richard at richard@futurehealth-research.com